Severe asthma is defined by the high treatment requirements to partly or fully control the clinical manifestations of disease. It remains a problem worldwide with a large burden for individuals and health services. The key to improving targeted treatments, reducing disease burden and improving patient outcomes is a better understanding of the pathophysiology and mechanisms of severe disease. The heterogeneity, complexity and difficulties in undertaking clinical studies in severe asthma remain challenges to achieving better understanding and better outcomes. In this review, we focus on the structural, mechanical and inflammatory abnormalities that are relevant in severe asthma.
INTRODUCTION
Severe asthma remains a worldwide problem with incomplete understanding of its pathophysiology. It is characterized by high requirements for treatment to partly or completely control severe and frequent symptoms with disproportionate use of medical resources. Asthma is a complex interplay between airway inflammation and airway remodelling which results in airway hyperresponsiveness (AHR)-variable and excessive airway narrowing. Severe asthma is also often associated with some degree of fixed airflow limitation. In Figure 1 , the marked thickening of the airway wall and widespread inflammatory infiltrate in severe asthma are contrasted with a similar-sized normal airway. These pathological changes result in reduced baseline lung function (in some cases) and severe, excessive airway narrowing when the smooth muscle is stimulated to contract, compared with normal airways or mild asthma (Fig. 2) where narrowing of the airways is limited.
The aim of investigating asthma pathophysiology is to understand the basis of AHR as well as incompletely reversible airflow obstruction. The current pathophysiological paradigm invokes remodelling, the sum of structural changes to the airway wall and lung parenchyma, to explain AHR and fixed airflow obstruction. The current research challenge is to sort out how and what structural changes cause AHR and fixed or variable airway narrowing, and how remodelling links with airway inflammation (Table 1) .
AIRWAY REMODELLING: THE SIMPLE AIRWAY TUBE MODEL
The airway can be conceptualized as a simple elastic 'tube' embedded within an elastic lung parenchyma. The elastic airways stretch (dilate) as the lung stretches, due to parenchymal tethering to the airway adventitia. In health, the elastic properties (compliance) of the lung parenchyma and airways are well matched (relative hysteresis), which underlies the relationship between lung volume and airway calibre. Therefore, changes in both the mechanical properties of the lung parenchyma and its attachments to the airway wall may contribute to AHR and fixed airflow obstruction.
The airway walls are clearly thickened in asthma, as demonstrated in many imaging and pathological studies. Increased airway wall thickness contributes to airway narrowing during airway smooth muscle (ASM) contraction via geometric effects. 1, 2 Thickening of the mucosal layer and the ASM potentiates the increase in airway resistance for any given amount of ASM shortening, because airway resistance is a function of radius (of the lumen) to the fourth power. Thickening of the airway wall outside of the ASM decreases the elastic pull of the attached lung (the springs are slackened), thereby reducing the force against which the ASM has to shorten. 3 ASM cell hypertrophy and hyperplasia 4, 5 potentially increase force generation even if the contractile properties remain normal. 6, 7 However, ASM is highly plastic, that is, it can change its contractile phenotype when exposed to inflammatory mediators, persistent contraction and altered length. [8] [9] [10] Thus, increased ASM bulk, combined with increased contractility that is optimized for any given ASM length (i.e. airway diameter) will contribute to AHR.
Increased tissue mass and altered composition of the airway wall, particularly of the extracellular matrix (ECM), may alter the airway wall mechanics and contribute to AHR and non-reversible airway narrowing. 11 Some studies suggest that airways from asthmatic (A) (B) Severe asthma
Mild asthma
Normal Figure 2 Airway responsiveness in non-asthmatic (normal) subjects and in those with mild and severe asthma. Normal airway responsiveness is characterized by a flat dose-response curves or those with limited maximal narrowing. Usually, doseresponse curves are displayed with the response expressed as percent change from the baseline value of lung function (most often forced expiratory volume in 1 s (FEV 1 )). In this example, the response is expressed as change in absolute terms (L). In mild asthma, maximal response is still detectable but it is increased compared with non-asthmatic subjects. There is also a small decrement in baseline lung function. In severe asthma, the decrement in baseline lung function is greater and a maximal response cannot be detected within the limits of safety of the test. In other words, the limit of inducible airway narrowing that is seen in normal subjects is increased in asthma, in relation to severity. These functional changes can be explained by the degree of remodelling observed in mild and severe asthma. patients are stiffer than those from non-asthmatic patients. 12, 13 This would prevent deep inspirations from dilating airways, but paradoxically it could also resist airway narrowing. Other studies suggest that airway stiffness is not greater in asthma 7 and the role of altered airway compliance remains uncertain. Compliance is not related to the severity of AHR 14 but is related to asthma symptoms. 13 In any event, an in vitro study of intact bronchial segments has shown that the increased thickness of the ASM layer is associated with increased maximal airway narrowing in asthma. 7 AIRWAY REMODELLING: THE COMPLEX BRANCHING SYSTEM Airway segments do not act in isolation but are integrated into the moving, branching system of airways acting in parallel and in series. Remodelling and inflammation of airways is likely distributed unevenly over this branching system in patients with severe asthma. 15 Computational models treating the lungs as an integrated complex unit of thousands of airway parenchymal units were used to explore small versus large airway function, airway closure and ventilation heterogeneity. Results suggest that both the large and peripheral airway compartments are relevant in severe asthma. 16 The role of the peripheral airways in AHR and fixed airway narrowing in severe asthma remains poorly understood. This is because the peripheral airways are the 'silent zone', contributing only about 10% of the total airway resistance. 17 Currently, they cannot be visualized by imaging and biopsy of the lung periphery is inherently confined to a tiny sample of the small airways and associated with significant risk (bleeding and pneumothorax).
Small airway function can be measured by ventilation heterogeneity (synonymous with inhomogeneity), which is the variability of 'specific ventilation' (ventilation per unit lung volume). Healthy lungs ventilate somewhat heterogeneously but in a highly spatially organized pattern along the gravitational gradient. Specific ventilation is greatest in the dependent zones, unless there is airway closure present, which can be thought of as the extreme end of the distribution of ventilation within a lung. 18 In asthma, ventilation is more heterogeneous compared with health, and with more widespread and patchy airway closure. [19] [20] [21] [22] Abnormalities of small airway function as measured by ventilation heterogeneity using the single-breath nitrogen washout (SBNW) and multiple-breath nitrogen washout (MBNW) are associated with asthma symptoms, severe asthma exacerbations, 23, 24 loss of control on withdrawal of treatment, 25 airway inflammation 26 and AHR. 26, 27 The relationship between small airway function and remodelling remains unknown. It has been proposed that peripheral airways influence symptoms, AHR and exacerbations due to airway inflammation and remodelling causing them to be unstable and prone to sudden closure. 28 The mechanism of this computational instability is that small airways are highly interconnected via parenchymal tissue (see Fig. 3 ); bronchoconstriction and closure in one airway affect its neighbours with the net result of small airways 'self-organizing' into zones of closure or severe hypoventilation. 18, 22 In severe asthma, these mechanisms may be exaggerated; however, this needs to be explored in future studies.
REMODELLING IN SEVERE ASTHMA
In severe asthma, airway walls are thicker on HRCT, 29 have more fibroblasts, larger mucous glands and increased ASM, [30] [31] [32] greater epithelial fragility 33 and increased blood vessels in the lamina propria. 34 There is ASM hyperplasia in severe asthma compared with Figure 3 Schema of how heterogeneity in inflammation and remodelling alters the mechanical function of small and large airways to cause excessive airway narrowing and airway closure. Excessive airway narrowing and closure is increased in severe asthma, and is based on greater heterogeneity of ventilation across the airway tree. Airway remodelling and inflammation, both distributed heterogeneously across the airway tree, lead to an inherent instability because airways are linked to each other by the alveolar elastic tissues. When bronchoconstriction occurs, some airways contract excessively, which then induces more airway narrowing and closure in its neighbours, creating a feed-forward loop. This leads to excessive and widespread narrowing and closure that occurs within zones or regions in the lungs that are easily detected by imaging. ASM, airway smooth muscle. controls 4, 5 and with less severe asthma. 5 There is also ASM hypertrophy in both severe and less severe asthma compared with controls. 5 ECM is increased in the ASM although this is in proportion to the increase in ASM. 5 Specific ECM proteins are also increased in asthma, although these may vary across the airway wall. 11, 35 Although structural changes in postmortem lungs following fatal asthma attacks may not necessarily be generalizable to severe asthma, there are similar changes in postmortem and biopsy tissue of non-fatal but clinically severe asthma, relative to mild cases and non-asthmatic individuals. 5, 31, 36 There are clear-cut differences in wall thickness in large airways between severe and mild-moderate asthma cases. The differences are less pronounced in the small airways, 5,31 possibly due to the small absolute size of the airways and variation in airway number and size. However, the small airways are more susceptible to severe narrowing and closure due to the greater wall area relative to the airway lumen area.
Localized regions of closure
The peripheral airways are tethered to the surrounding lung parenchyma which maintains airway calibre and prevents excessive narrowing and closure. Postmortem, lung resection and transbronchial biopsy studies in severe asthma show neutrophilic, eosinophilic and lymphocytic inflammation and remodelling in the peripheral airways extending to the adventitia and lung, 33, [37] [38] [39] closely resembling that seen in the large airways. Remodelling of the ASM in the small airways 32,37 also resembles ASM remodelling in the large airways. 15 Inflammation in the small airways could break adjacent adventitial attachments, described in fatal asthma, 40 and reduce elastic recoil pressure, described in long-standing asthma 12, 41, 42 and during asthma exacerbations. 43 Reduced lung elastic recoil pressure also explains the reduced lung density on computed tomography (CT) scans, increased small airway collapse and gas trapping during expiration and fixed airway narrowing, all of which are well described in severe asthma. 44 Recently, increased contractile elements have been documented in the lung parenchyma in asthma. 45 
FIXED AIRFLOW OBSTRUCTION IN SEVERE ASTHMA
Fixed reduction in lung function is highly variable between asthmatic individuals. 46 An increased rate of forced expiratory volume in 1 s (FEV 1 ) loss is found in some 47, 48 but not all studies, 49 even in severe asthma. 50 Reduced lung function, related to asthma severity, tracks from infancy and childhood into adult life. [51] [52] [53] In severe asthma, risk factors for loss of FEV 1 are exacerbations, 54 sputum eosinophilia, adult-onset disease, longer duration of asthma, 55 AHR, 56 mucus hypersecretion, 48 blood eosinophilia and bronchial wall thickening 57 and sputum neutrophilia. 58 In a longitudinal study, the age-adjusted FEV 1 decline was increased in up to 15% of severe asthmatic individuals, 59 compared with around 2% in the general asthmatic population.
Airflow obstruction has a developmental origin that likely starts in utero, as reticular basement membrane (RBM) thickening and inflammation are present in wheezy infants 60, 61 and ASM remodelling has been observed in preschool children who later develop asthma. 62 A number of birth cohorts have shown abnormal lung function in infants who later develop asthma. 53, 63, 64 These changes are observed before the onset of allergic sensitization, 65 the greatest risk factor for childhood-onset asthma. 66 Thus, remodelling and inflammation may be parallel processes that may independently contribute to asthma. Persistence or acceleration of both inflammation and remodelling in early childhood, which are then modified by childhood exposures such as viruses and diet, could underlie the development of severe asthma and its persistence into adulthood. Adequate control of symptoms is not a guarantee of protection against loss of lung function.
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THE NATURE OF THE RELATIONSHIP BETWEEN INFLAMMATION AND REMODELLING
How airway inflammation and remodelling relate to each other is uncertain. The traditional paradigm that airway inflammation drives airway remodelling leading to AHR and fixed airflow obstruction derives from the relation of persistent eosinophilic inflammation and decreased FEV 1 56, 57 and from cross-sectional studies. 69 Sputum neutrophilia is also an independent risk factor for reduced lung function. Eosinophilic, but not neutrophilic, inflammation is strongly regionally associated with increased ASM within the bronchial tree. 15 The drivers of inflammation could be IgE-or IgG-mediated sensitization to aeroallergens or small molecules, abnormal epithelial repair 70 and/or epithelial mesenchymal transformation. 71 Alternately, inflammation and remodelling may be complementary processes, rather than being cause and effect. The relationships between ASM remodelling and reduced FEV 1 , to clinical severity but not duration, suggests an early and perhaps preexisting abnormality of airway structure that strongly influences severity but which requires inflammation to manifest clinically. This may explain the ability of antiinflammatory treatments to reverse asthma symptoms and variable airflow limitation without reversing fixed airflow limitation or altering the rate of decline of lung function.
Altered airway structure may itself stimulate inflammation. 35 Remodelling involves degradation and repair of ECM and proliferation of fibroblasts and myofibroblasts. The action of matrix metalloproteinases on ECM releases bioactive fragments that are pro-inflammatory and increase neo-vascularization. For example, elastin fragments have a wide range of effects and are proproliferative and pro-inflammatory and further stimulate matrix degradation via stimulating matrix metalloproteinase release. 72 Decreased collagen IV in asthmatic airways reduces the level of one of its bioactive fragments, tumstatin, in airway fluid and airway biopsies. 73 Tumstatin inhibits vascularization and prevents angiogenesis, AHR, inflammatory cell infiltrate and mucus secretion in a mouse model of asthma. 73 ASM cells from asthmatic individuals have proproliferative activity 74 and increased chemotactic activity for mast cells. 75 
INFLAMMATION HETEROGENEITY IN SEVERE ASTHMA
Heterogeneity of inflammation in asthma was recognized even in 1922 by Huber and Koessler 30 in airway tissue from fatal asthma. They described the association between allergy and eosinophilic airway inflammation, but also mixed infiltrates of eosinophils and neutrophils. This heterogeneity is clinically relevant in relation to the variable responses to inhaled corticosteroids and to potential effects on remodelling and AHR.
A cluster analysis based on symptom control and sputum eosinophilia to group statistically similar individuals together was applied to a UK asthmatic cohort with a wide range of disease severity and age of onset. 76 One cluster had childhood-onset asthma associated with atopy and active airway eosinophilia whose symptoms and sputum eosinophilia were concordant. In the other three clusters, symptoms and sputum eosinophilia were discordant. One cluster had eosinophilia and late-onset asthma, but with few symptoms. The other two clusters were non-eosinophilic; one characterized by obesity, late-onset disease and female gender, while the other was characterized by early-onset disease and atopy. 76 Another cluster analysis of 378 adult asthmatic patients enriched with severe disease from the Severe Asthma Research Programme (SARP) 77 identified 112 variables including those from bronchial lavage and biopsy. Six clusters were identified, three containing severe asthmatic patients; early-onset allergic asthma with low lung function and eosinophilic inflammation; later-onset, mostly severe asthma with nasal polyps and eosinophilia; and those with persistent inflammation in blood and bronchoalveolar lavage (BAL) fluid and exacerbations despite high systemic corticosteroid use. The fact that the clusters could be identified by using only FEV 1 and age of onset of asthma reinforces the importance and clinical utility of lung function in severe asthma.
However, the clusters identified by these analyses are still subject to bias as they are dependent on the variables that are used for the analyses. In a nonselected general population in which a wide range of measures of respiratory symptoms and illness were used, clusters were dependent on the input variables. While these studies neither inform on effects of treatment nor specifically address severe asthma, they do show that the label of 'asthma' is non-specific and occurs in a high percentage of clusters identified with widely varying characteristics. 78, 79 Interestingly, both the cluster analysis of severe asthma 77 and general population cluster analyses identified a subgroup of overweight females likely to have severe asthma or be labelled as having asthma. 78 These studies confirm that the clinical diagnosis of asthma, long known to be variable in its presentation and expression, encompasses different pathological mechanisms that drive the disease throughout life and highlights the importance of thorough physiological characterization of patients in routine clinical practice.
ALLERGIC AIRWAY INFLAMMATION IN SEVERE ASTHMA
Endobronchial biopsy of proximal airways in severe asthma has shown persistent type 2 inflammation characterized by airway eosinophils, lymphocytes, mast cells and associated thickening of the RBM despite regular use of oral corticosteroids. 80 Interestingly, eosinophilia in severe asthma was similar to that in steroidnaïve, mild asthma with a tendency to increased airway neutrophils and half had no eosinophilic inflammation. 80 In a study of 80 subjects with severe asthma, asthma onset before 12 years of age was associated with atopy (98% vs 76%), higher serum IgE and increased eosinophils, lymphocytes and mast cells in the airway wall 81 compared with onset after 12 years. In those with later-onset asthma, half had no airway eosinophilia and tended to have lower lung function and a history of near-fatal attacks. 81 These findings were recently replicated in the larger SARP severe asthma cohort where approximately half had persistent type 2 inflammation (increased sputum eosinophils, exhaled nitric oxide, blood eosinophils, IgE and serum periostin with more atopy and AHR). 77 Activation of type 2 airway inflammation in the context of severe asthma is summarized in Figure 4 .
The persistence of eosinophilia despite corticosteroid treatment in severe asthma is unexplained. Eotaxin, a chemokine that recruits eosinophils and TH-2 cells, is elevated in severe asthma and greater expression in airway epithelial cells 82 and fibroblasts 83 may drive eosinophilia despite steroid treatment. Type 2 innate lymphoid cells (ILC2) and innate immune activation of structural cells, such as airway epithelium, also drive type 2 immune responses in asthma in the absence of atopy and sputum eosinophilia, and may contribute to disease severity and steroid resistance. ILC2 cells release more IL-5, -4 and -13 compared with CD4 TH-2 cells. ILC2 cells are increased in blood but there are twice as many ILC2 cells in the sputum in subjects with severe asthma. 84 Similarly, children with severe asthma have 10-fold more ILC2 in the BAL than in the blood. 85 Mechanisms to switch off type 2 immune responses in severe asthma may be impaired. Natural killer (NK) cells have innate immune functions similar to CD8 cells, in that they express perforin and granzyme and may play an important role in switching off activated immune cells by inducing apoptosis in granulocytes. 86 They also induce apoptosis in eosinophils and are reduced in the blood of subjects with severe asthma compared with mild asthma and controls. 87 Lipoxin A 4 , an anti-inflammatory cytokine which enhances NK cell-induced eosinophil apoptosis, is reduced in the BAL of subjects with severe asthma. 88 Such mechanisms may contribute to treatment resistance in severe asthma.
Mast cells are activated when the IgE antibodies bind with allergen via the FcεR1 high affinity receptors. 89 In severe asthma, mast cells express more chymase and tryptase compared with normal subjects and increased numbers of intraepithelial mast cells have been found at endobronchial biopsy in the airways in severe asthma compared with mild asthma. 90 Mast cell activation is enhanced in severe asthma, with elevated levels of mast cell-derived prostaglandin D 2 in BAL, 91 which is able to activate both mast cells themselves as well as ILC2 cells via the chemoattractant receptor-homologous molecule expressed on T helper type 2 cells. 91 Inflammation can also affect the airway epithelium. Exposure to IL-13 induces mucus metaplasia contributing to mucus hypersecretion and impaired mucus clearance. 92 Mucus hypersecretion is an important symptom in severe asthma which contributes to increased luminal narrowing and is associated with FEV 1 decline. 93 The importance of the type 2 inflammation in severe asthma is clearly shown by the clinical and anti-inflammatory efficacy of monoclonal antibodies that specifically target these pathways. Omalizumab binds IgE in the blood 94 and reduces exacerbation frequency without improving lung function in subjects with severe allergic asthma with persistent allergic inflammation, not controlled by inhaled corticosteroids. 95 Blocking the actions of the cytokine IL-5 with mepolizumab in severe asthma markedly reduces blood eosinophils and, to a lesser extent, tissue eosinophilia and reduces acute exacerbations by approximately 50%. 96, 97 Dupilumab is a monoclonal antibody that blocks the IL-4/IL-13 receptor. It has a potentially larger effect on exacerbation frequency and lung function in moderate and severe asthma that is independent of eosinophilia. 98 Most recently, the results of a phase 2 trial of a monoclonal antibody against thymic stromal lymphopoietin (TSLP), Tezepelumab, was published. 99 TSLP is released by the airway epithelium not only in response to allergen exposure, but also in response to viral infection and diesel particle exposure. In moderate-to-severe symptomatic asthma, Tezepelumab reduced exacerbations by 60-70% and resulted in a small increase in lung function. 99 These treatments are very promising for those with severe asthma and persistent allergic airway inflammation. However, other mechanisms also need to be considered in non-allergic inflammation and severe asthma. 
NON-ALLERGIC AIRWAY INFLAMMATION IN SEVERE ASTHMA
The importance of non-allergic airway inflammation in severe asthma is increasingly recognized but is much less well characterized. Non-allergic inflammation is enhanced in severe asthma, with a mixed inflammatory infiltrate of eosinophils and neutrophils, increased CXCL-8 and interferon (IFN)-γ-positive CD4 (TH-1) 100 and CD4 TH-17 cells and IL-13. 101 Messenger RNA for a suppressor of type 1 inflammation, secretory leukocyte protease inhibitor, is reduced in epithelial brushings in severe asthma. 101 High nitro-oxidative stress is also increased in BAL in severe asthma compared with mild/moderate asthma and controls, and is associated with airway inflammation. 102 It is increased by IL-13 (a TH-2 cytokine) and IFN-γ, which also correlate with airflow obstruction. 103 The innate immune response likely plays an important role in non-allergic asthma. It involves the airway epithelium, fibroblasts, smooth muscle cells and innate immune cells, particularly dendritic cells and ILC. 89 ILC are non-T, non-B lineage negative lymphocytes that migrate to the airways in response to environmental triggers 86 (see Fig. 4 ). They are quite plastic cells in their responses to stimuli, which is modified by their immune environment.
Increased sputum neutrophils may be the result of increased innate immune activation as suggested by the correlations between sputum neutrophil number or CXCL-8 (IL-8) and innate immune activation markers toll-like receptor (TLR)-2/4 and CD-14 in sputum. 104 The innate immune system may be activated by chronic airway 'infection'. Potentially pathogenic bacteria such as Haemophilus, Moraxella and Streptococcus in sputum in severe asthma correlate with sputum CXCL-8 and neutrophils. 105 ILC are increased in the BAL of obese patients with severe asthma 106 and produce IL-17 which drives airway neutrophilia and may cause smooth muscle contraction. 107 The precise role of these mechanisms in severe asthma is yet to be determined.
Obesity is an independent risk factor for severe asthma and is associated with non-type 2 inflammation. Obese asthmatic patients have later-onset disease, corticosteroid refractoriness, 108 less atopy, more severe symptoms and increased medication use. 109 Obesity alone may worsen nitro-oxidative stress in asthma and therefore non-type 2 inflammation. 110 In asthma, elevated serum IL-6 is associated with increased body weight, with lower lung function and greater exacerbation risk independent of obesity. 111 
CONCLUSIONS
The pathophysiology of severe asthma, characterized by severe AHR, abnormal fixed lung function, high treatment requirements and persisting symptoms, is due to a complex interaction between inflammation, airway remodelling and altered lung mechanics. Airway inflammation in severe asthma is highly complex, involving both adaptive and innate systems, and greater understanding of inflammation has helped clinicians to better understand clinical disease (phenotypes) and to better treat severe asthma patients. More importantly, however, there is a great need to determine how inflammation and airway remodelling interact, which results in the abnormal physiology of AHR in severe asthma. The magnitude of the structural changes to the airway wall is increased, and more heterogeneously distributed in severe asthma. Furthermore, the mechanical properties of the lung parenchyma and the interaction between airways and peribronchial structures are more abnormal in severe asthma and amplify the mechanical consequences of airway remodelling. These processes result in airway narrowing that is excessive, easily triggered and often irreversible, the complex mechanics of which are increasingly better understood.
There are many important unanswered questions regarding the pathophysiology of severe asthma. As the authors of the Lancet Commission on asthma suggest, 112 we need to think differently and consider different paradigms to make significant progress in treatment and finding cures in severe asthma. The long-standing paradigm of eosinophilic inflammation leading to remodelling, which then leads to AHR, is clearly inadequate. We need to know what the relationships between type 1 and type 2 inflammation and remodelling are, and what roles inflammation and remodelling play in AHR and the clinical expression of severe asthma. There are too few clinical studies to address mechanistic questions. We still do not know what the mechanisms of irreversible airway narrowing are, if remodelling (particularly of the ASM) is reversible, how the pathology of asthma is distributed across the airway tree and how best to treat remodelling or its progression. Finally, we need to know what the early life influences and ageing effects on severe asthma pathophysiology are, if we are to have a chance of preventing asthma, particularly severe asthma, and irreversible airflow obstruction. 
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